

# Federico Alberici

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3202899/federico-alberici-publications-by-citations.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

66

papers

2,008

citations

22

h-index

44

g-index

99

ext. papers

2,690

ext. citations

5

avg, IF

4.65

L-index

| #  | Paper  | IF   | Citations |
|----|--|------|-----------|
| 66 | A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. <i>Kidney International</i> , <b>2020</b> , 97, 1083-1088  | 8.9  | 238       |
| 65 | Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. <i>Journal of Autoimmunity</i> , <b>2015</b> , 57, 60-5   | 15.5 | 170       |
| 64 | Management of Patients on Dialysis and With Kidney Transplantation During the SARS-CoV-2 (COVID-19) Pandemic in Brescia, Italy. <i>Kidney International Reports</i> , <b>2020</b> , 5, 580-585   | 4.1  | 145       |
| 63 | Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. <i>Lancet, The</i> , <b>2011</b> , 378, 338-46  | 40   | 136       |
| 62 | IgG4 immune response in Churg-Strauss syndrome. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 390-3  | 2.4  | 128       |
| 61 | A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection. <i>Kidney International</i> , <b>2020</b> , 98, 20-26  | 9.9  | 118       |
| 60 | Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. <i>Rheumatology</i> , <b>2015</b> , 54, 1153-60  | 3.9  | 72        |
| 59 | Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. <i>Nature Communications</i> , <b>2019</b> , 10, 5120   | 17.4 | 71        |
| 58 | A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. <i>Rheumatology</i> , <b>2011</b> , 50, 899-905  | 3.9  | 62        |
| 57 | Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 1440-1447                                | 2.4  | 54        |
| 56 | Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial. <i>Blood</i> , <b>2015</b> , 126, 1163-71  | 2.2  | 50        |
| 55 | PTPN22 R620W polymorphism in the ANCA-associated vasculitides. <i>Rheumatology</i> , <b>2012</b> , 51, 805-12  | 3.9  | 50        |
| 54 | Kidney transplant patients with SARS-CoV-2 infection: The Brescia Renal COVID task force experience. <i>American Journal of Transplantation</i> , <b>2020</b> , 20, 3019-3029  | 8.7  | 48        |
| 53 | Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2018</b> , 29, 283-294   | 12.7 | 48        |
| 52 | Adjuvant low-dose interleukin-2 (IL-2) plus interferon- $\gamma$ in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC). <i>Journal of Immunotherapy</i> , <b>2014</b> , 37, 440-7 | 5    | 46        |
| 51 | Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series. <i>Journal of Autoimmunity</i> , <b>2015</b> , 57, 24-9  | 15.5 | 44        |
| 50 | Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 80-5  | 2.4  | 39        |

|    |   |      |    |
|----|---|------|----|
| 49 | Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 1584-6   | 2.4  | 38 |
| 48 | Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2021</b> ,   | 12.7 | 32 |
| 47 | Impact of rituximab trials on the treatment of ANCA-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , <b>2014</b> , 29, 1151-9  | 4.3  | 29 |
| 46 | Chronic periaortitis with thoracic aorta and epiaortic artery involvement: a systemic large vessel vasculitis?. <i>Rheumatology</i> , <b>2015</b> , 54, 2004-9  | 3.9  | 26 |
| 45 | Chronic periaortitis associated with membranous nephropathy: clues to common pathogenetic mechanisms. <i>Clinical Nephrology</i> , <b>2010</b> , 74, 485-90   | 2.1  | 24 |
| 44 | Peripheral inflammatory arthritis in patients with chronic periaortitis: report of five cases and review of the literature. <i>Rheumatology</i> , <b>2008</b> , 47, 315-8   | 3.9  | 20 |
| 43 | The role of analytical methods for the determination of trace elements in environmental biomonitors. <i>Microchemical Journal</i> , <b>2002</b> , 73, 131-152   | 4.8  | 20 |
| 42 | Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial. <i>PLoS ONE</i> , <b>2017</b> , 12, e0185880  | 3.7  | 19 |
| 41 | Genetic aspects of anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , <b>2015</b> , 30 Suppl 1, i37-45  | 4.3  | 19 |
| 40 | Lupus nephritis and B-cell targeting therapy. <i>Expert Review of Clinical Immunology</i> , <b>2017</b> , 13, 951-962   | 5.1  | 17 |
| 39 | Genetics of ANCA-associated vasculitides: HLA and beyond. <i>Clinical and Experimental Rheumatology</i> , <b>2014</b> , 32, S90-7   | 2.2  | 17 |
| 38 | Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2017</b> , 139, 1684-1687.e10 | 11.5 | 15 |
| 37 | Orofacial granulomatosis treated with low-level laser therapy: a case report. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , <b>2012</b> , 113, e25-9  | 2    | 15 |
| 36 | and SARS-CoV-2 Co-Infection: A Common Feature in Transplant Recipients?. <i>Vaccines</i> , <b>2020</b> , 8,   | 5.3  | 14 |
| 35 | Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1077-1083   | 2.4  | 13 |
| 34 | Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?. <i>Autoimmunity Reviews</i> , <b>2020</b> , 19, 102671   | 13.6 | 13 |
| 33 | FcεReceptor 3B (FCGR3B) copy number variations in patients with eosinophilic granulomatosis with polyangiitis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2016</b> , 137, 1597-1599.e8  | 11.5 | 12 |
| 32 | A large-scale genetic analysis reveals an autoimmune origin of idiopathic retroperitoneal fibrosis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2018</b> , 142, 1662-1665  | 11.5 | 12 |

|    |  |      |    |
|----|--|------|----|
| 31 | Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1670-1680  | 9.5  | 10 |
| 30 | Co-infection of chlamydia pneumoniae and mycoplasma pneumoniae with SARS-CoV-2 is associated with more severe features. <i>Journal of Infection</i> , <b>2021</b> , 82, e4-e7  | 18.9 | 10 |
| 29 | Update on ANCA-associated vasculitis: from biomarkers to therapy. <i>Journal of Nephrology</i> , <b>2019</b> , 32, 871-882   | 4.8  | 9  |
| 28 | Chronically administered immunotherapy with low-dose IL-2 and IFN-alpha in metastatic renal cell carcinoma: a feasible option for patients with a good prognostic profile. <i>Oncology</i> , <b>2009</b> , 76, 69-76                                 | 3.6  | 9  |
| 27 | Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-alpha in patients with renal cell carcinoma. <i>Medical Oncology</i> , <b>2009</b> , 26, 38-44  | 3.7  | 9  |
| 26 | Rituximab in Membranous Nephropathy. <i>Kidney International Reports</i> , <b>2021</b> , 6, 881-893  | 4.1  | 9  |
| 25 | COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab. <i>Nephrology Dialysis Transplantation</i> , <b>2021</b> , 36, 1758-1760   | 4.3  | 9  |
| 24 | Correspondence on Immunogenicity and safety of anti-SARS-Cov-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, e158 | 2.4  | 8  |
| 23 | Variable Expressivity of HNF1B Nephropathy, From Renal Cysts and Diabetes to Medullary Sponge Kidney Through Tubulo-interstitial Kidney Disease. <i>Kidney International Reports</i> , <b>2020</b> , 5, 2341-2350                                    | 4.1  | 7  |
| 22 | Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). <i>European Respiratory Journal</i> , <b>2021</b> , 57,   | 13.6 | 7  |
| 21 | Role of chemotherapy with gemcitabine plus 5-fluorouracil and chemoimmunotherapy in metastatic renal cell cancer (mRCC). <i>Journal of Immunotherapy</i> , <b>2007</b> , 30, 780-6   | 5    | 6  |
| 20 | Slowly progressive anti-neutrophil cytoplasmic antibody-associated renal vasculitis: clinico-pathological characterization and outcome. <i>CKJ: Clinical Kidney Journal</i> , <b>2021</b> , 14, 332-340  | 4.5  | 5  |
| 19 | Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 74, 295  | 9.5  | 5  |
| 18 | Management of patients on dialysis and with kidney transplant during COVID-19 coronavirus infection. <i>Polki</i> , <b>2020</b> , 9, 117-120   | 0.3  | 4  |
| 17 | FCGR2A single nucleotide polymorphism confers susceptibility to childhood-onset idiopathic nephrotic syndrome. <i>Immunology Letters</i> , <b>2018</b> , 193, 11-13  | 4.1  | 4  |
| 16 | FCGR3B polymorphism predicts relapse risk in eosinophilic granulomatosis with polyangiitis. <i>Rheumatology</i> , <b>2020</b> , 59, 3563-3566  | 3.9  | 3  |
| 15 | Genetically distinct clinical subsets, and associations with asthma and eosinophil abundance, within Eosinophilic Granulomatosis with Polyangiitis   |      | 3  |
| 14 | Risk factors and action thresholds for the novel coronavirus pandemic. Insights from the Italian Society of Nephrology COVID-19 Survey. <i>Journal of Nephrology</i> , <b>2021</b> , 34, 325-335   | 4.8  | 2  |

|    |   |     |   |
|----|---|-----|---|
| 13 | Association of a polymorphism of the Fcγ-receptor 2A (FCGR2A) gene with chronic periaortitis. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 37, 222-226   | 2.2 | 2 |
| 12 | OP0148 MEPOLIZUMAB FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A RETROSPECTIVE REAL-WORLD EUROPEAN STUDY ON 142 PATIENTS. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 94-95                   | 2.4 | 1 |
| 11 | The Authors Reply. <i>Kidney International Reports</i> , <b>2020</b> , 5, 1376  | 4.1 | 1 |
| 10 | Expanding the variability of the ADPKD-GANAB clinical phenotype in a family of Italian ancestry. <i>Journal of Nephrology</i> , <b>2021</b> , 1   | 4.8 | 1 |
| 9  | Occupational Exposures and Smoking in Eosinophilic Granulomatosis With Polyangiitis: A Case-Control Study. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 1694-1702  | 9.5 | 1 |
| 8  | Therapies for Membranous Nephropathy: A Tale From the Old and New Millennia.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 789713   | 8.4 | 1 |
| 7  | SARS-CoV-2 infection in dialysis and kidney transplant patients: immunological and serological response.. <i>Journal of Nephrology</i> , <b>2022</b> , 1  | 4.8 | 0 |
| 6  | The Impact of Anti-SARS-CoV-2 Vaccine in Patients with Systemic Lupus Erythematosus: A Multicentre Cohort Study. <i>Vaccines</i> , <b>2022</b> , 10, 663  | 5.3 | 0 |
| 5  | Magnetic resonance imaging in central nervous system vasculitis in a patient affected by crioglobulin-negative hepatitis C virus infection: A likely correlation. <i>Neuroradiology Journal</i> , <b>2018</b> , 31, 193-195 | 2   |   |
| 4  | Lessons From the Clinic: ADPKD Genetic Test Unraveling Severe Phenotype, Intrafamilial Variability, and New, Rare Causing Genotype.. <i>Kidney International Reports</i> , <b>2022</b> , 7, 895-898                         | 4.1 |   |
| 3  | Genetics of ANCA-Associated Vasculitis. <i>Rare Diseases of the Immune System</i> , <b>2020</b> , 19-32   | 0.2 |   |
| 2  | THU0249 CLINICAL FEATURES AND RENAL PROGNOSIS IN LUPUS NEPHRITIS PATIENTS UNDERGOING A REPEATED BIOPSY: RESULTS OF 103 RE-BIOPSIES IN 438 PATIENTS. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 351.1-352   | 2.4 |   |
| 1  | MO040ASSOCIATION OF A TNFSF13B (BAFF) REGULATORY REGION SINGLE NUCLEOTIDE POLYMORPHISMS WITH RESPONSE TO RITUXIMAB IN ANCA-ASSOCIATED VASCULITIS. <i>Nephrology Dialysis Transplantation</i> , <b>2016</b> , 31, i45-i46    | 4.3 |   |